Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
13 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06153238 | A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma | completed | Phase 1 | 322 | SandozINDUSTRY | 18 | Jul 7, 2026 | clinicaltrials |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 130 | GenmabINDUSTRY | 20 | May 19, 2026 | clinicaltrials |
| NCT04516447 |
| A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer(MUIR) |
| recruiting |
| Phase 1 |
| 172 |
| K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY |
| 7 |
| Apr 7, 2026 |
| clinicaltrials |
| NCT02514447 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | completed | Phase 1 / Phase 2 | 123 | G1 Therapeutics, Inc.INDUSTRY | 8 | Sep 25, 2025 | clinicaltrials |
| NCT06551064 | Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients(Dahlia) | active not recruiting | Phase 1 | 96 | Formycon AGINDUSTRY | 11 | Sep 4, 2025 | clinicaltrials |
| NCT07130916 | A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer | recruiting | Phase 1 | 20 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 3 | Aug 19, 2025 | clinicaltrials |
| NCT03560531 | A Study of ZN-c5 in Subjects With Breast Cancer | completed | Phase 1 / Phase 2 | 181 | Zeno Alpha Inc.INDUSTRY | 9 | Aug 9, 2024 | clinicaltrials |
| NCT03446417 | A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer | completed | Phase 1 | 34 | Zeno Pharmaceuticals, Inc.INDUSTRY | 2 | Jan 25, 2024 | clinicaltrials |
| NCT04091503 | Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma | completed | Phase 1 | 30 | Center Trials & Treatment EuropeNETWORK | 3 | Apr 25, 2023 | clinicaltrials |
| NCT05622058 | A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer | terminated | Phase 1 | 6 | Aileron Therapeutics, Inc.INDUSTRY | 4 | Feb 27, 2023 | clinicaltrials |
| NCT04022876 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | terminated | Phase 1 | 35 | Aileron Therapeutics, Inc.INDUSTRY | 7 | Oct 10, 2022 | clinicaltrials |
| NCT04176757 | A Study of ZN-c5 in Participants With Breast Cancer | completed | Phase 1 | 35 | Zeno Alpha Inc.INDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials